Intravitreal bevacizumab for severe vaso-occlusive retinopathy in systemic lupus erythematosus
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Won June | - |
dc.contributor.author | Cho, Hee Yoon | - |
dc.contributor.author | Lee, Yoon Jung | - |
dc.contributor.author | Lee, Byung Ro | - |
dc.contributor.author | Shin, Jae Pil | - |
dc.date.accessioned | 2022-07-16T11:57:04Z | - |
dc.date.available | 2022-07-16T11:57:04Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2013-01 | - |
dc.identifier.issn | 0172-8172 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/163739 | - |
dc.description.abstract | Severe vaso-occlusive retinopathy is a relatively rare form of retinopathy in systemic lupus erythematosus (SLE). We report two patients with severe vaso-occlusive retinopathy in SLE who were treated with intravitreal bevacizumab (IVB). (Patient 1) A 35-year-old woman presented with left visual loss and was diagnosed with SLE after systemic evaluation. Despite systemic immunosuppressive therapy, retinal vascular obstruction progressed and neovascularization of the disk (NVD) developed. The patient was treated with IVB and pan retinal photocoagulation. The progression of vascular obstruction ceased and regressed. (Patient 2) A 24-year-old man with SLE presented with left visual loss. There was retinal vascular obstruction with macular edema in both eyes, and then the patient was treated with IVB. One month after injection, minimal capillary nonperfusion increased to 10 disk area, and 5 months later, neovascularization elsewhere (NVE) developed in the right eye. Six months after injection, vitreous hemorrhage with florid NVE and NVD developed in the left eye. In selected severe vaso-occlusive retinopathy in SLE patients, IVB may be an adjuvant option for treatment. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER HEIDELBERG | - |
dc.title | Intravitreal bevacizumab for severe vaso-occlusive retinopathy in systemic lupus erythematosus | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Cho, Hee Yoon | - |
dc.contributor.affiliatedAuthor | Lee, Byung Ro | - |
dc.identifier.doi | 10.1007/s00296-011-2139-9 | - |
dc.identifier.scopusid | 2-s2.0-84872282650 | - |
dc.identifier.wosid | 000313016500037 | - |
dc.identifier.bibliographicCitation | RHEUMATOLOGY INTERNATIONAL, v.33, no.1, pp.247 - 251 | - |
dc.relation.isPartOf | RHEUMATOLOGY INTERNATIONAL | - |
dc.citation.title | RHEUMATOLOGY INTERNATIONAL | - |
dc.citation.volume | 33 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 247 | - |
dc.citation.endPage | 251 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | ANTIPHOSPHOLIPID SYNDROME | - |
dc.subject.keywordPlus | VEIN OCCLUSION | - |
dc.subject.keywordPlus | MANIFESTATION | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | PATIENT | - |
dc.subject.keywordAuthor | Bevacizumab | - |
dc.subject.keywordAuthor | Lupus retinopathy | - |
dc.subject.keywordAuthor | Severe vaso-occlusive retinopathy | - |
dc.subject.keywordAuthor | Systemic lupus erythematosus | - |
dc.subject.keywordAuthor | Vascular endothelial growth factor | - |
dc.subject.keywordAuthor | Vasculitis | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s00296-011-2139-9 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.